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Background Anti-retroviral therapy (ART) regimes for HIV are associated with raised levels of circulating triglycerides
(TGs) in western populations. However, there are limited data on the impact of ART on cardiometabolic risk in sub-
Saharan African (SSA) populations.
Methods Pooled analyses of 14 studies comprising 21 023 individuals, on whom relevant cardiometabolic risk factors
(including TG), HIV and ART status were assessed between 2003 and 2014, in SSA. The association between ART and raised
TG (>2.3 mmol/L) was analysed using regression models.
Findings Among 10 615 individuals, ART was associated with a two-fold higher probability of raised TG (RR 2.05, 95% CI
1.51–2.77, I2 = 45.2%). The associations between ART and raised blood pressure, glucose, HbA1c, and other lipids were
inconsistent across studies.
Interpretation Evidence from this study confirms the association of ART with raised TG in SSA populations. Given the
possible causal effect of raised TG on cardiovascular disease (CVD), the evidence highlights the need for prospective studies
to clarify the impact of long term ART on CVD outcomes in SSA.
Received 16 October 2017; Revised 8 April 2018; Accepted 10 April 2018
Key words: Antiretroviral therapy, cardiovascular disease, HIV, lipids, sub-Saharan Africa, triglycerides.
Background
Epidemiological studies of environmental and genetic risk fac-
tors indicate that elevated triglycerides (TGs), remnant chol-
esterol or TG-rich lipoproteins may be causal risk factors for
cardiovascular disease (CVD) [1–3]. Anti-retroviral therapy
(ART) is associated with dyslipidaemia, including increased
levels of circulating TGs in populations of European decent
[4–6]. As such, long-term ART may be associated with
increased risk of CVD. Indeed, observational evidence sug-
gests that certain ART regimens may be associated with
increased risk of CVD in European populations [7].
However, in sub-Saharan Africa (SSA), a region with the
highest burden of HIV and where access to ART has substan-
tially increased over the last decade, the association between
ART and TGs has not been clarified. Importantly, the relation-
ship between ART and risk factors for CVD in populations
from SSAmay bemore complex because of differences in car-
diometabolic risk profiles, HIV strains, efficacy of ART and
environmental factors [8–19]. It is therefore crucial to assess
the association between ART and cardiovascular risk factors
in SSA populations – to inform strategies to control the rising
burden of CVD in the region.
We previously conducted a systematic review to provide
a preliminary assessment of the relationship between HIV
and ART with a set of cardiometabolic risk factors [20]. In
this paper, we extend this work to synthesize existing evi-
dence using individual participant data (IPD) pooled analyses
to more reliably assess the magnitude and direction of
association between ART and raised TGs and other risk fac-
tors for cardiometabolic disease in SSA.
Methods
Data sources and inclusion criteria
We invited 57 investigators to contribute IPD for pooled
analysis: 52 investigators who had collaborated in a previous
systematic review of the association between HIV, ART and
cardiometabolic risk factors [20], and five investigators iden-
tified through personal communication with other colla-
borators. Briefly, we included studies conducted in SSA
that had collected data on HIV/ART status and the relevant
cardiometabolic risk factors among black Africans aged 13
years or older. Studies were excluded if they lacked a com-
parison group, or had too few (<10) or no participants with
a risk factor based on a defined cut-off, or had a very small
sample size (<10 participants).
Data collation
We requested data on cardiometabolic risk factors [blood
pressure (BP), lipids, glucose and glycated haemoglobin
(HbA1c)], HIV infection and ART status. We also collected
additional variables for adjustment (Table 1). Data were
checked for plausibility and consistency and, when neces-
sary, collaborators were contacted for clarification before
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analysis. We converted all variables measured on other
scales to the SI scale (mmol/L, %, mm Hg or Kg/m2).
Definition of outcomes and exposure
The outcomes for this study were binary cardiometabolic
risk factors defined according to predefined clinical cut-offs
[21–26]. We analysed the following risk factors: raised TGs
(>2.3 mmol/L), raised low-density lipoprotein (LDL ⩾3.3
mmol/L), raised total cholesterol (TC >5.2 mmol/L) and
low high-density lipoprotein (HDL <1.3 mmol/L for
women and HDL <1.0 mmol/L for men). We also analysed
raised BP (>140/90 mm Hg), raised blood glucose (fasting
blood glucose ⩾7.0 mmol/L or random blood glucose
⩾11.1 mmol/L) and raised HbA1c (⩾6.5%). The exposures
of interest were HIV infection status (positive or negative)
and ART use. HIV infection status was defined as presented
in each study. An individual was considered to have
untreated HIV infection if they were HIV-positive and had
never received ART medication. In addition, individuals
recorded as receiving ART were considered to be
HIV-infected. We defined ART use as a receipt of ART
medication at the time of cardiometabolic risk factor
measurement.
Statistical analysis
We conducted a two-step IPD pooled analysis, analysing each
dataset separately to obtain study-level estimates, before
combining them using random-effects models of meta-
analysis. We fitted Poisson regression models with robust
sandwich estimators of variance for each outcome to obtain
study-specific risk ratios (RRs) and prevalence ratios (PRs)
for ART use and untreated HIV infection [27, 28]. RRs and
PRs are collectively referred to as RR hereafter. We used
multilevel mixed models to adjust for clustering of individuals
within households in two cross-sectional studies and to
account for correlation in repeatedmeasurements in one lon-
gitudinal study included in the analyses.
In our primary analysis, we assessed the association
between ART and each cardiometabolic risk factor by com-
paring individuals receiving ART (ART+) with individuals not
receiving ART. Individuals not receiving ART were either
untreated HIV-positive individuals (in studies of HIV-positive
individuals only) or a combination of untreated HIV-positive
individuals and HIV-negative (HIV-) individuals (in studies
including both groups). In sensitivity analyses, we also com-
pared associations between individuals receiving ART and
HIV-negative individuals, and between individuals receiving
ART and untreated HIV-positive individuals. We also com-
pared untreated HIV-positive individuals with HIV-negative
individuals to assess the impact of HIV infection on cardio-
metabolic risk independent of ART use.
All models were adjusted for body mass index (BMI), age
and sex. In a subgroup of studies where data were available,
we also adjusted for alcohol consumption, current smoking
status, education level, fruit and vegetable consumption,
physical activity and socio-economic position. Additionally,
where data were available for lipid and glucose outcomes,
we adjusted for lipid- and glucose-lowering medication,
respectively. For BP as an outcome, we adjusted for BP-
lowering medication where data were available. Further,
for each cardiometabolic risk factor studied as an outcome
variable, the other cardiometabolic risk factors were add-
itionally adjusted for.
Table 1. Data requested for estimating the magnitude and direction of association between anti-retroviral therapy (ART) and selected cardiometabolic
risk factors in sub-Saharan Africa
Cardiometabolic risk factor HIV and ART information Additional information
TG level HIV status Sex
Total cholesterol level Date of first positive HIV test Age
HDL level Date of last negative HIV test Country of origin
LDL level WHO HIV stage Ethno-linguistic group
BMI Serial CD4 counts with dates Education level
SBP Serial viral load measurements with
dates
Smoking history
DBP ART status Alcohol consumption
Blood glucose level (FBG/RBG) Date of ART initiation Hepatitis B status
HbA1c level Type of ART with dates of use Hepatitis C status
Lipid-lowering medication and duration, glucose-lowering
medication and duration, blood pressure-lowering medication
and duration
Date of blood draw for lipid
measurement
TG, triglycerides; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; BMI, body mass index; SBP, sys-
tolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; RBG, random blood glucose; HbA1c, glycated haemoglo-
bin; ART, antiretroviral therapy; WHO, World Health Organization.
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To pool the adjusted RRs, we estimated a weighted
average of study-specific log (adjusted RR) incorporating
between-study heterogeneity according to the method of
DerSimonian and Laird [29]. The I2 statistic was used to assess
the heterogeneity between study-specific estimates [30].
A predetermined set of study-level characteristics were
assessed as potential sources of heterogeneity between
studies using meta-regression: study type (population-based,
clinic-based), study size, year the study was conducted, loca-
tion of study (West, East, Central or Southern Africa), sex
distribution (proportion of men), mean participant BMI
and mean participant age. Lastly, we conducted sensitivity
analyses to assess whether a single study could have influ-
enced pooled RR results excessively by excluding each
study from the pooled analysis in turn, and comparing
results with and without the study in question.
All analyses were performed using STATA 13.1 (Stata,
College Station, TX, USA).
Ethics
This study received ethical approval from the Human
Biology Research Ethics Committee at the University of
Cambridge, UK (Application No: HBREC.2015.05), and
each primary study obtained informed consent from
participants.
Results
We received data for 20 studies and included 14 studies
conducted between 2003 and 2014 in the current analysis
(Fig. 1). Overall, the pooled data comprised 21 023 partici-
pants aged 13–107 years, with generally fewer men than
women but with varying proportions for each cardiometa-
bolic risk factor studied (Table 2). The number of individuals
and proportion of men and women included in the analyses
varied by cardiometabolic risk factors because not all studies
had data on all risk factors, and because of missing data
within studies. Apart from one all-women study, the pro-
portion of men across all studies ranged between 22% and
49%. In the primary analyses (comparing individuals on
ART to individuals not receiving ART), the number of parti-
cipants included ranged from 6364 with data on glucose to
10 620 with data on TC (Table 2).
From the above, 10 615 [36% men; age range 17–100
years; mean age 41.4 years (SD 14.0)] individuals from
eight studies provided data for analyses of the association
between ART and raised TG. Of these, 1552 were on
ART, 1413 (91%) of whom provided data on ART regimen
(Table 3). Among those with data on ART regimen, 80%
were on two nucleoside reverse transcriptase inhibitors
(NRTIs) [mainly zidovudine (AZT) and lamivudine, 80%]
and one non-nucleoside reverse transcriptase inhibitor
(NNRTI) [mainly efavirenz (EFV) or nevirapine (NVP),
87%] (two NRTIs + one NNRTI); while 13% received two
NRTIs and one protease inhibitor (PI) (two NRTIs + one
PI) (Table 3). In all, 87% of the individuals with TG data,
who were on ART, and provided ART regimen data, were
on a non-PI combination (predominantly, two NRTIs +
one NNRTI), while 13% were on a combination including
a PI. The prevalence of raised TG was 10.5% (95% CI 7.5–
13.9), overall; 13.2% (95% CI 8.1–19.2) among individuals
on ART and 8.4% (95% CI 4.9–12.6) among individuals not
on ART.
Association between ART and raised TG
Compared with individuals not receiving ART (i.e. untreated
HIV-positive individuals only, or untreated HIV-positive indi-
viduals and HIV negative individuals combined), individuals
receiving ART were two times more likely to have raised
TG (RR 2.05, 95% CI 1.51–2.77) (Fig. 2a). This association
did not vary substantially across studies (I2 45.2%) and was
consistent when ART users were compared with HIV-
negative individuals only and with untreated HIV-positive
individuals only (Fig. 2b, c). Additional analyses comparing
untreated HIV-positive individuals with HIV-negative indivi-
duals found no association between untreated HIV infection
and TG (Fig. 2d) suggesting that the association between
ART and raised TG is independent of HIV infection.
Association between ART drug class and raised
TG
Additionally, we performed sensitivity analyses to assess
whether there was a difference in probability of raised TG
between individuals receiving an ART combination that
included a PI and individuals receiving a combination not
including a PI. In one of three studies with adequate num-
bers of individuals on PIs to allow analyses, we found
some indication that individuals receiving a PI combination
are more likely to have raised TG compared with individuals
on a non-PI combination (Dave study: RR 2.10, 95% CI
1.06–4.02). However, this association was confounded by
duration of ART. Individuals on ART drug combinations
that included a PI had been on ART, on average, twice as
long as individuals on non-PI combinations. Thus, when dur-
ation of ART was adjusted for, the association became non-
significant (RR 1.5, 95% CI 0.72–3.11). There was no differ-
ence in the significance of the effect of PIs relative to non-PIs
with and without adjustment for duration of ART in the
other studies. It was, however, not possible to establish
the time spent on a particular class of ART as the duration
reported was simply time spent on all ART. Considering PIs
are currently used as second-line drugs, individuals on PIs
are likely to have spent some time on first-line non-PI com-
binations. Thus, in these data, there was no evidence that PIs
were more strongly associated with raised TG than NNRTIs
after adjusting for treatment duration. Additionally, the
probability of raised TG was not significantly different
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between individuals whose regimen included AZT com-
pared with stavudine and EFV compared with NVP.
Association between ART and other
cardiometabolic risk factors
The estimates of association of ART (in the primary ana-
lyses) with raised LDL (RR 1.39, 95% CI 1.04–1.87) and
raised TC (RR 1.85, 95% CI 1.20–2.84), though significant,
were markedly heterogeneous (I2 78.2% and 87.7%, respect-
ively) across studies (Fig. 2a). There was no evidence of an
association between ART and raised BP, glucose, HbA1c
or low HDL (Fig. 2a).
When ART users were compared separately with HIV-
negative individuals and with untreated HIV-positive indivi-
duals, the association of ART with raised LDL, low HDL
and raised TC was inconsistent across studies (Fig. 2b,c).
There was no association between ART and raised glucose
or HbA1c when comparing individuals on ART with
HIV-negative individuals or untreated HIV-positive indivi-
duals (Fig. 2b,c). Additionally, ART was associated with a
lower risk of raised BP when individuals on ART were com-
pared with HIV-negative individuals (Fig. 2b). However,
there was no evidence of association between ART and
raised high BP in comparison with untreated HIV-positive
individuals (Fig. 2c).
Sources of heterogeneity and individual study
influence on pooled association between ART and
cardiometabolic risk factors
In primary analyses comparing individuals receiving ART to
all other individuals, the magnitude of association between
ART and raised TG ranged from 0.81 to 6.17, with a moder-
ate level of heterogeneity (I2 = 45.2%) (Supplementary
Fig. S1). We found no statistically significant study-level
determinants of between-study heterogeneity in the
pooled association between ART and TG (Supplementary
Table S1). Additionally, no single study substantially influ-
enced the pooled estimate of the association between ART
and raised TG (Supplementary Table S2). In comparisons
of individuals receiving ART with HIV-negative individuals,
we found only minimal between-study heterogeneity in the
association between ART and raised TG (I2 = 21.6%)
(Supplementary Fig. S2). This heterogeneity was not
explained by any of the study-level variables assessed
(Supplementary Table S3), and the pooled association was
not substantially influenced by any particular study
Fig. 1. Study selection for individual participant data pooled analysis to assess the association of HIV and anti-retroviral therapy with
cardiometabolic risk in sub-Saharan Africa.
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Table 2. Characteristics of 14 studies included in the pooled analyses to assess the association between HIV/anti-retroviral therapy (ART) and selected cardiometabolic risk factors in sub-Saharan Africa
Number of participants
Risk factor Study/investigator Study period Study type Location Age range
Percentage
of men HIV-negative HIV-positive
Untreated
HIV-positive on ART
Raised TGa THUSA42 2004 Population based Southern Africa 15–90 42 1440 204 0 0
Sani43 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte44 2007 Population based Southern Africa 20–77 49 251 108 0 0
Mutimura45 2007 Clinic based East Africa 25–70 0 112 361 0 0
Dave46 2008 Clinic based Southern Africa 19–68 22 0 0 404 551
Stehouwer47 2008 Clinic based East Africa 18–74 34 0 0 379 191
Kruger-Fourie48 2010 Population based Southern Africa 35–98 35 850 168 107 61
Walsh49 2011 Population based Southern Africa 25–65 22 669 254 209 45
GPC50 2011 Population based East Africa 17–100 43 4954 547 339 208
Pefura51 2011 Clinic based West Africa 18–67 40 0 0 138 204
DDS52 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 8875 2149 1991 1552
Raised LDLb THUSA 2004 Population based Southern Africa 15–90 42 1421 201 0 0
Sani 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte 2007 Population based Southern Africa 20–77 49 249 107 0 0
Mutimura 2007 Clinic based East Africa 25–70 0 106 316 0 0
Dave 2008 Clinic based Southern Africa 19–68 22 0 0 403 550
Stehouwer 2008 Clinic based East Africa 18–74 37 0 0 337 192
Kruger-Fourie 2010 Population based Southern Africa 35–98 35 850 168 107 61
Walsh 2011 Population based Southern Africa 25–65 22 661 254 209 44
GPC 2011 Population based East Africa 17–100 43 4954 547 339 208
Pefura 2011 Clinic based West Africa 18–67 40 0 0 138 204
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 8840 2100 1948 1551
Low HDLc THUSA 2004 Population based Southern Africa 15–90 42 1464 206
Sani 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte 2007 Population based Southern Africa 20–77 49 251 108 0 0
Mutimura 2007 Clinic based East Africa 25–70 0 184 511 0 0
Dave 2008 Clinic based Southern Africa 19–68 22 0 0 404 551
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Stehouwer 2008 Clinic based East Africa 18–74 36 0 0 338 181
Kruger-Fourie 2010 Population based Southern Africa 35–98 35 851 168 107 61
Walsh 2011 Population based Southern Africa 25–65 22 669 254 209 45
GPC 2011 Population based East Africa 17–100 43 4954 547 339 208
Pefura 2011 Clinic based West Africa 18–67 40 0 0 138 204
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 8972 2301 1950 1542
Raised TCd THUSA 2004 Population based Southern Africa 15–90 42 1439 204 0 0
Sani 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte 2007 Population based Southern Africa 20–77 49 251 108 0 0
Mutimura 2007 Clinic based East Africa 25–70 0 183 475 0 0
Dave 2008 Clinic based Southern Africa 19–68 22 0 0 404 551
Stehouwer 2008 Clinic based East Africa 18–74 35 0 0 381 195
Kruger-Fourie 2010 Population based Southern Africa 35–98 35 850 167 106 61
Walsh 2011 Population based Southern Africa 25–65 22 669 254 209 45
GPC 2011 Population based East Africa 17–100 43 4954 547 339 208
Pefura 2011 Clinic based West Africa 18–67 40 0 0 138 204
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 8945 2262 1992 1556
Raised blood pressuree Africa Centre (2003)53 2003 Population based Southern Africa 17–72 32 1435 649 0 0
THUSA 2004 Population based Southern Africa 15–90 42 1505 209 0 0
Sani 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte 2007 Population based Southern Africa 20–77 49 258 112 0 0
Mutimura 2007 Clinic based East Africa 25–70 0 187 536 0 0
Dave 2008 Clinic based Southern Africa 19–68 22 0 0 391 547
Stehouwer 2008 Clinic based East Africa 16–72 35 0 0 409 306
Kruger-Fourie 2010 Population based Southern Africa 35–98 35 872 169 108 61
Africa Centre (2010)53 2010 Population based Southern Africa 14–107 31 5752 1823 0 0
Walsh 2011 Population based Southern Africa 25–65 22 667 250 206 44
GPC 2011 Population based East Africa 17–100 43 4945 548 337 211
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 16 220 4803 1866 1461
Raised blood glucosef THUSA 2004 Population based Southern Africa 15–90 42 1421 204 0 0
Sani 2005 Clinic based West Africa 20–50 47 0 0 100 100
Schutte 2007 Population based Southern Africa 20–77 49 251 108 0 0
Mutimura 2007 Clinic based East Africa 25–70 0 188 536 0 0
(Continued)
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Table 2 (cont.)
Number of participants
Risk factor Study/investigator Study period Study type Location Age range
Percentage
of men HIV-negative HIV-positive
Untreated
HIV-positive on ART
Dave 2008 Clinic based Southern Africa 19–68 22 0 0 404 551
Stehouwer 2008 Clinic based East Africa 18–76 32 0 0 93 151
Faurholt-Jepsen54 2009 Clinic based East Africa 13–89 55 1227 677 597 80
Kruger-Fourieg 2010 Population based Southern Africa 35–98 35 859 168 107 61
Walshg 2011 Population based Southern Africa 25–65 22 677 251 206 45
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 5222 2451 1822 1180
Raised HbA1ch Kruger-Fourie 2010 Population based Southern Africa 35–98 35 863 168 107 61
Walshg 2011 Population based Southern Africa 25–65 22 681 253 208 45
GPCg 2011 Population based East Africa 17–97 43 4939 546 339 207
DDS 2014 Population based Southern Africa 18–91 29 599 507 315 192
Total 7082 1474 969 505
TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; HbA1c, glycated haemoglobin.
a Raised TG defined as TG >2.3 mmol/L.
b Raised LDL defined as LDL ⩾3.3 mmol/L.
c Low HDL defined as HDL <1.3 mmol/L (women) and HDL <1.0 mmol/L (men).
d Raised TC defined as TC >5.2 mmol/L.
e Raised BP defined as systolic blood pressure ⩾140 mm Hg or diastolic blood pressure ⩾90 mm Hg.
f Raised glucose defined as glucose ⩾7.0 mmol/L (fasting) or glucose ⩾11.1 mmol/L (non-fasting).
g Estimates for ART not available because of too few cases of raised glucose; GPC, General Population Cohort; THUSA, Transition and Health during Urbanization in South Africa; DDS, Durban
Diabetes Study.
h Raised HbA1c defined as HbA1c ⩾6.5%.
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Table 3. Number of individuals (with data on triglycerides) receiving specific antiretroviral therapy drug class combination and the most common regimen in pooled analyses of the association between ant-retroviral therapy
and cardiometabolic risk in sub-Saharan Africa
Study
TotalSani Dave Pefura GPC Stehouwer DDS Kruger-Fourie Walsh
Number on ART 100 551 204 208 191 192 61 45 1552
Number for which ART regimen
data are available (% of number on
ART)
100 (100) 549 (99.6) 204 (100) 208
(100)
186 (97.4) 166 (86.5) 0 (0) 0 (0) 1413
(91)
Two NRTIs + one NNRTI (%)a 99 (99) 445 (81) 138 (68) 201 (97) 119 (64) 128 (77) _ _ 1130
(80)
One NRTI + one NNRTI (%)a 13 (8) _ _ 13 (1)
Two NRTIs + one PIb (%)a 1 (1) 94 (17) 66 (32) 6 (3) 13 (17) 2 (1) _ _ 182
(13)
One NRTIs + one PI (%)a 2 (1) _ _ 2 (0)
One or two NNRTI only (%)a 2 (1) _ _ 2 (0)
One, two or three NRTIs only (%)a 1 (0) 54 (29) 19 (11) _ _ 74 (5)
One NRTI + one NNRTI + one PI
(%)a
1 (0) _ _ 1 (0)
One NNRTI + one PI (%)a 9 (2) _ _ 9 (0)
Most common regimen D4T or
AZT/3TC/
NVP
D4T or AZT/3TC/EFV;
D4T or AZT/3TC/
NVP
D4T or AZT/3TC/EFV;
D4T or AZT/3TC/
NVP
AZT/
3TC/
NVP
TDF, or D4T, or AZT/3TC/EFV;
TDF, or D4T, or AZT/3TC/NVP
TDF/FTC/EFV _ _
Number on most common regimen
(%)c
73 (74) 437 (98) 138 (100) 172 (86) 119 (100) 120 (94) _ _
ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; GPC, General Population Cohort;
DDS, Durban Diabetes Study; D4T, stavudine; AZT, zidovudine; 3TC, lamivudine; NVP, niverapine; EFV, efavirenz; TDF, tenofovir; FTC, emtricitabine.
a Percentage of number for which ART regimen data are available.
b The PI was lopinavir/ritonavir, 80% of the time.
c Percentage of number receiving 2NRTIs + 1NNRTI.
_ Regimen data not provided.
Some non-zero proportions are recorded as 0% and some percentages do not add up to 100%, because of rounding errors.
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(Supplementary Table S4). Similarly, in comparison of ART
users with untreated HIV-positive individuals, between-study
heterogeneity in the association between ART and raised
TG was low (I2 = 38.0%) (Supplementary Fig. S3) and not
associated with any of the study-level characteristics
(Supplementary Table S5). The pooled RR was also not influ-
enced by any one study (Supplementary Table S6). In com-
parisons of untreated HIV-positive individuals with
HIV-negative individuals, as discussed above, we found no
association between untreated HIV and raised TG. This
lack of association was consistent across studies (I2 =
43.0%) (Supplementary Fig. S4) and was not significantly influ-
enced by any of the study characteristics assessed
(Supplementary Table S7). Lastly, the pooled magnitude of
association was not influenced by a single study
(Supplementary Table S8).
As indicated above, there was significant between-study
heterogeneity in the association between ART and all the
other cardiometabolic risk factors in the primary analysis,
except for raised blood glucose and HbA1c. The observed
heterogeneity was not associated with any of the study-level
factors assessed, nor was the pooled measure of association
influenced by one study alone, except for raised BP where
the magnitude of association with ART tended to be higher
in population studies compared with clinic-based studies
(Supplementary Tables S1 and S2).
Discussion
In these pooled analyses of 10 615 individuals, ART was
independently associated with a twofold higher probability
Fig. 2. Association of anti-retroviral therapy and untreated HIV infection with selected cardiometabolic risk factors in sub-Saharan
Africa.
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of raised TG. This could have important implications for the
burden of CVD in SSA as access to, and duration on, ART
increases in this population, highlighting the need to better
understand the effect of long-term ART on TG and its
impact on the burden of CVD in SSA.
Our findings are broadly consistent with earlier reports,
including a study among black African women in rural
South Africa and a meta-analysis of clinical trials in
European-descent populations [31, 32]. These studies sug-
gested that first-line ART is associated with raised choles-
terol and TG [31, 32]. In addition, a study of metabolic
complications in a European-descent population found that
the use of combined NNRTI and PI was associated with a
fivefold higher prevalence of hypertriglyceridaemia [33]. In
our study, 87% of the participants on ART were either on
two NRTIs and one NNRTI (the standard first-line
anti-HIV drugs recommended across SSA) or a non-standard
combination of NRTIs and NNRTIs; while only 13%
received drug combinations including a PI [34]. PIs, currently
used as second-line ART drugs, have been the most cited in
studies measuring CVD among HIV-infected people receiv-
ing ART in other parts of the world [7, 33]. In this study,
we found no evidence that ART combinations including
PIs were more strongly associated with raised TG than
non-PI combinations.
Many mechanisms by which ART may lead to raised TG
levels have been proposed. It is thought that ARTmay reduce
the clearance of TG from circulation through impairment of
lipoprotein lipase activity in experimental studies [35].
Additionally, ART may cause accumulation of the sterol-
sensing transcription factor SREBP, the chief regulator of
lipid homeostasis, which contributes to an increase in hepatic
intracellular lipids [36]. Further, ARTmay increase the level of
circulating TGby alteringmitochondrial proliferation,morph-
ology and mitochondrial DNA content, or inhibiting the deg-
radation of and increasing hepatic secretion of ApoB, themain
lipoprotein for transportation of lipids [37–41].
Evidence of the effect of prolonged ART use on CVD risk
is currently limited to a few studies in western populations.
One study found a relative rate of myocardial infarction of
between 0.98 and 1.13 per year of NNRTI exposure and
1.10 and 1.23 per year of PI exposure [7]. Similar to this
study, our findings suggest that longer duration of ART
may confer greater risk of raised TG. However, the poten-
tial impact of ART on CVD risk mediated specifically
through raised TG may be inferred from studies of the effect
of TG on CVD. For example, in a recent meta-analysis, the
odds of coronary heart disease (CHD) was nearly doubled
in individuals with TG values in the top third of the popula-
tion compared with those in the bottom third [2].
Additionally, in another study, an increase of 1 mmol/L
in TG was associated with increases of between 14%
and 37% in CVD risk after adjustment for HDL [1].
Extrapolating the results of the studies above to our study,
with TG higher in ART users by 1.11 mmol/L than the
rest of the population on average, ART may be associated
with 16–41% increase in CVD risk.
We note, however, that there is a paucity of published
population data on the prevalence of dyslipidaemia, including
raised TG, in SSA. Estimates of raised TG prevalence ranging
from 5% to 20% have been reported in rural East Africa and
urban West Africa, respectively [42–44]. This variation likely
reflects differences in study design as well as potential real
differences between populations. Further, available evidence
consistently shows higher rates of hyperglyceridaemia
among HIV-infected individuals receiving ART compared
with untreated HIV-positive individuals and HIV-negative
individuals [43, 45, 46]. Estimates of the prevalence of
hypertriglyceridemia of between 14% and 42% have been
reported among individuals receiving ART [43, 45, 46].
The heterogeneity is perhaps explained by underlying differ-
ences between populations in addition to differences in the
duration of ART use – for example, comorbidities, socio-
economic factors and healthcare systems.
The strength of this study is that it is the largest to date to
assess the association between ART and cardiometabolic
risk in SSA using IPD. In addition, we defined cardiometa-
bolic risk factors according to clinically relevant cut-offs.
Our findings may therefore be relevant for the clinical
care of patients. Further, use of IPD enabled a more com-
prehensive adjustment for potential confounders including
BMI and socio-demographic factors, as well as behavioural
risk factors at the individual level. Importantly, the study
assessed data on the class of ART thereby shedding more
light on the impact of ART drug class on lipids, which is rele-
vant to HIV patient treatment and care.
However, the study has some limitations. First, the major-
ity of the studies included in the pooled analysis were cross-
sectional. This precludes an analysis of the temporal
relationship between ART use and the cardiometabolic
risk factors studied. Second, our results may have been con-
founded by fasting status, as some of the studies included in
the pooled analyses provided non-fasted lipids and glucose
measurements. However, studies of fasting participants
and studies of unfasted participants have reported only
minor differences in the strength of associations between
TG and CHD [2]. This, and the fact that non-fasted lipids
and glucose were presented by only two studies, suggests
that the impact of potential confounding due to differences
in fasting status on the validity of our results is likely to be
minimal.
In summary, this study provides evidence of association
between ART and raised TG in SSA. Given the increasing
use of ART and a potentially causal association between
raised TG and CVD outcomes, our findings support the
need to transition to new ARV drugs, such as dolutegravir,
that have shown less adverse effects on lipids [47].
Importantly, the findings highlight the need for prospective
studies to clarify the impact of long-term ART and its inter-
play with other risk factors on CVD risk in SSA. In the
cambridge.org/gheg
interim, it might be beneficial to strengthen the monitoring
of lipid levels in individuals receiving ART.
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/gheg.2018.7
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